[{"address1": "2533 South Coast Highway 101", "address2": "Suite 210", "city": "Cardiff", "state": "CA", "zip": "92007", "country": "United States", "phone": "858 400 8470", "website": "https://www.viracta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.", "fullTimeEmployees": 40, "maxAge": 86400, "priceHint": 4, "previousClose": 0.569, "open": 0.5795, "dayLow": 0.564, "dayHigh": 0.649, "regularMarketPreviousClose": 0.569, "regularMarketOpen": 0.5795, "regularMarketDayLow": 0.564, "regularMarketDayHigh": 0.649, "beta": 0.387, "forwardPE": -0.6379591, "volume": 128941, "regularMarketVolume": 128941, "averageVolume": 107175, "averageVolume10days": 101360, "averageDailyVolume10Day": 101360, "bid": 0.5877, "ask": 0.6423, "bidSize": 100, "askSize": 100, "marketCap": 24553104, "fiftyTwoWeekLow": 0.43, "fiftyTwoWeekHigh": 1.68, "fiftyDayAverage": 0.765, "twoHundredDayAverage": 0.7586, "currency": "USD", "enterpriseValue": 9296126, "floatShares": 24663481, "sharesOutstanding": 39272400, "sharesShort": 668437, "sharesShortPriorMonth": 686731, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.017, "heldPercentInsiders": 0.027609998, "heldPercentInstitutions": 0.51873, "shortRatio": 7.3, "shortPercentOfFloat": 0.0217, "impliedSharesOutstanding": 39272400, "bookValue": 0.143, "priceToBook": 4.3720274, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -47990000, "trailingEps": -1.23, "forwardEps": -0.98, "lastSplitFactor": "285:1000", "lastSplitDate": 1614211200, "enterpriseToEbitda": -0.179, "52WeekChange": -0.5531915, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "VIRX", "underlyingSymbol": "VIRX", "shortName": "Viracta Therapeutics, Inc.", "longName": "Viracta Therapeutics, Inc.", "firstTradeDateEpochUtc": 1127827800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ed5f69f9-939f-3d89-84c4-600b43f665a9", "messageBoardId": "finmb_38720301", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6252, "targetHighPrice": 6.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.0, "targetMedianPrice": 5.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 39566000, "totalCashPerShare": 1.007, "ebitda": -51882000, "totalDebt": 18857000, "quickRatio": 1.308, "currentRatio": 1.354, "debtToEquity": 170.19, "returnOnAssets": -0.51491, "returnOnEquity": -1.5432601, "freeCashflow": -23709500, "operatingCashflow": -36401000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]